<DOC>
	<DOCNO>NCT02242032</DOCNO>
	<brief_summary>The purpose study assess safety tolerability P-321 Ophthalmic Solution subject mild moderate dry eye disease .</brief_summary>
	<brief_title>Study Safety Tolerability P 321 Ophthalmic Solution Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This single-center , dose escalation , randomize , double-masked , placebo-controlled , Phase 1/2a trial design evaluate safety tolerability P-321 Ophthalmic Solution subject mild moderate dry eye 4-weeks treatment 8 schedule clinic visit . This study conduct consecutive dose escalation follow concentration P-321 Ophthalmic Solution give two time day via ocular instillation : 0.0005 % ( Cohort 1 ) , 0.0015 % ( Cohort 2 ) , 0.005 % ( Cohort 3 ) , 0.01 % ( Cohort 4 ) . Up 48 subject enrol four consecutive cohort . Subjects randomize P-321 Ophthalmic Solution placebo 3:1 ratio . Safety tolerability assessment , drug plasma concentration drug urine concentration evaluate throughout study cohort .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Individuals gender race eligible study participation : 1 . Provide write informed consent . 2 . Are 18 80 year age . 3 . Corneal fluorescein stain score ≥2/15 NEI/Industry scale 4 . Conjunctival lissamine stain score ≥ 2/18 NEI/Industry scale 5 . Schirmer &lt; 10mm/5min 6 . Are willing able follow instruction present require study visit duration study . 7 . Female patient child bear potential must negative urine pregnancy test Screening agree use medically acceptable form birth control . Male subject sexually active must willing use highly effective contraception ( i.e. , less 1 % failure rate ) heterosexual intercourse Day 1 completion study . 8 . Have history Dry Eye Disease eye support previous clinical diagnosis selfreported history subjective complaint least 4 month prior Screening , low tear volume , ocular staining . 9 . Have document history topical lubricant least daily desire use topical lubricant past 4 month . 10 . Have normal lid anatomy Individuals eligible study participation : 1 . Have anterior segment eye disease except primary dry eye . 2 . Patients identifiable suspected secondary dry eye , i.e. , document likely systemic , ocular , pharmacologic , posttraumatic , postsurgical , external cause dry eye symptom ocular surface stain . 3 . Patients current punctal plug , punctal occlusion , history nasolacrimal duct obstruction exclude . 4 . Have history glaucoma intraocular pressure ( IOP ) &gt; 25 mmHg Screening Visit ( Visit 1 ) history elevate IOP within past year prior Visit 1 5 . Contact lenses wear previous 30 day Treatment Phase study . 6 . Use lid scrub ( include baby shampoo ) 7 . Known hypersensitivity study investigational medicinal product , formulation excipients , include amiloride relate drug allergy component study drug . 8 . Any significant chronic illness , opinion Principal Investigator ( PI ) , could interfere study parameter . 9 . Use investigational product device within 30 day prior Screening Visit study . 10 . Those unable opinion PI comply fully study requirement complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>dry eye disease</keyword>
</DOC>